To determine whether humans with ALD have elevated FGF21 levels similar to mice with alcohol-induced hepatic steatosis and liver injury, we measured serum FGF21 concentrations in 24 patients with ASH, in 20 patients with alcoholic cirrhosis (AC) with no fatty liver on ultrasound/CT scan, and in 26 nondrinking healthy subjects with no liver disease. Here, FGF21 is linked to fatty liver disease.